Loading...
XNYS
BHC
Market cap1.66bUSD
May 22, Last price  
4.50USD
1D
0.45%
1Q
-38.44%
Jan 2017
-69.01%
Name

Bausch Health Companies Inc

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
0.17
EPS
—
Div Yield, %
—
Shrs. gr., 5y
0.89%
Rev. gr., 5y
2.05%
Revenues
9.52b
+8.69%
935,536,0001,070,475,000842,818,000757,178,000820,430,0001,181,237,0002,463,450,0003,546,626,0005,769,605,0008,263,500,00010,498,800,0009,674,000,0008,724,000,0008,380,000,0008,601,000,0008,027,000,0008,434,000,0008,124,000,0008,757,000,0009,518,000,000
Net income
-46m
L-92.23%
89,027,000203,938,000195,539,000199,904,000176,455,000-208,193,000159,559,000-116,025,000-866,142,000913,500,000-266,200,000-2,409,000,0002,404,000,000-4,148,000,000-1,783,000,000-559,000,000-937,000,000-212,000,000-592,000,000-46,000,000
CFO
1.60b
+54.75%
498,109,000521,934,000340,853,000204,325,000360,897,000263,191,000676,473,000656,578,0001,041,957,0002,294,700,0002,200,400,0002,087,000,0002,290,000,0001,501,000,0001,501,000,0001,111,000,0001,426,000,000-728,000,0001,032,000,0001,597,000,000
Dividend
Nov 10, 20101 USD/sh
Earnings
Jul 30, 2025

Profile

Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
URL
https://www.bauschhealth.com/
IPO date
Sep 20, 1994
Employees
19,900
Domiciled in
CA
Incorporated in
CA

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
9,518,000
8.69%
8,757,000
7.79%
8,124,000
-3.68%
Cost of revenue
3,398,000
6,058,000
5,518,000
Unusual Expense (Income)
NOPBT
6,120,000
2,699,000
2,606,000
NOPBT Margin
64.30%
30.82%
32.08%
Operating Taxes
239,000
221,000
83,000
Tax Rate
3.91%
8.19%
3.18%
NOPAT
5,881,000
2,478,000
2,523,000
Net income
(46,000)
-92.23%
(592,000)
179.25%
(212,000)
-77.37%
Dividends
Dividend yield
Proceeds from repurchase of equity
(24,000)
644,000
BB yield
0.82%
-28.33%
Debt
Debt current
2,674,000
450,000
432,000
Long-term debt
22,085,243
20,517,917
Deferred revenue
Other long-term liabilities
19,965,000
1,029,000
949,000
Net debt
1,493,000
21,588,243
20,385,917
Cash flow
Cash from operating activities
1,597,000
1,032,000
(728,000)
CAPEX
(337,000)
(215,000)
(268,000)
Cash from investing activities
(454,000)
(2,145,000)
(303,000)
Cash from financing activities
(868,000)
1,475,000
(474,000)
FCF
6,074,000
1,674,000
1,295,932
Balance
Cash
1,181,000
947,000
564,000
Long term investments
Excess cash
705,100
509,150
157,800
Stockholders' equity
(556,000)
(296,000)
101,000
Invested Capital
22,873,000
23,631,000
21,844,000
ROIC
25.29%
10.90%
11.03%
ROCE
27.27%
11.49%
11.77%
EV
Common stock shares outstanding
368,000
364,900
362,000
Price
8.06
0.50%
8.02
27.71%
6.28
-77.25%
Market cap
2,966,080
1.35%
2,926,498
28.73%
2,273,360
-77.06%
EV
5,416,080
25,454,741
23,611,277
EBITDA
7,387,000
3,963,000
4,000,000
EV/EBITDA
0.73
6.42
5.90
Interest
1,388,000
1,328,000
1,464,000
Interest/NOPBT
22.68%
49.20%
56.18%